HSIN-YUN SUNKo W.-C.Tsai J.-J.Lee H.-C.Liu C.-E.Wong W.-W.Su S.-C.Ho M.-W.Cheng S.-H.Yang C.-H.Lin Y.-H.Miao W.-J.WANG-HUEI SHENGCHIEN-CHING HUNG2021-12-012021-12-0120090002-9270https://www.scopus.com/inward/record.uri?eid=2-s2.0-65449153663&doi=10.1038%2fajg.2008.159&partnerID=40&md5=55c232a8b3963384fe413f0704d944e4https://scholars.lib.ntu.edu.tw/handle/123456789/588908Objectives: We aimed to assess the impact of nationwide hepatitis B virus (HBV) vaccination program on the seroprevalence of HBV infection among human immunodeficiency virus (HIV)-positive persons in a country where most HBV exposure occurs during the perinatal period or in early childhood.Methods: Data on HBV surface antigen (HBsAg), anti-HBV surface (anti-HBs), anti-HBV core (anti-HBc), and anti-hepatitis C virus (anti-HCV) antibody were retrospectively collected from 3,164 HIV-positive and 2,594 HIV-negative persons between 2004 and 2007. Comparisons of serological markers of HBV and HCV were made between HIV-positive and -negative adults born before and after the implementation of the HBV vaccination program in Taiwan in July 1984.Results: Compared with HIV-negative persons, the adjusted odds ratio for HBsAg seropositivity was 1.100 (95% confidence interval, 0.921-1.315) among HIV-positive persons. Although the seroprevalence of anti-HCV antibody remained similar between HIV-positive persons born before and those born after 1984, the seroprevalence of HBsAg declined from 20.3 to 3.3% in HIV-positive persons (P=0.001) and from 15.5 to 8.5% in HIV-negative persons (P=0.001). Despite the high seroprevalence of anti-HCV antibody (97.1%) in HIV-positive injecting drug users (IDUs), there was no statistically significant difference in the seroprevalence of HBsAg (5.6% vs. 8.5%, P0.75) or anti-HBc antibody (40.7% vs. 27.9%, P0.14) between HIV-positive IDUs and HIV-negative persons who were born after 1984.Conclusions: Our study showed a significant decline of seroprevalence of HBV infection among both HIV-negative and -positive persons who were born in the era of the nationwide HBV vaccination in Taiwan. ? 2009 by the American College of Gastroenterology.[SDGs]SDG3hepatitis B antibody; hepatitis B core antibody; hepatitis B surface antigen; hepatitis B vaccine; hepatitis C antibody; hepatitis B surface antigen; Human immunodeficiency virus antibody; adolescent; adult; aged; article; childhood; chronic hepatitis; comparative study; controlled study; female; hepatitis B; human; Human immunodeficiency virus 1; Human immunodeficiency virus 1 infection; Human immunodeficiency virus infected patient; major clinical study; male; perinatal period; priority journal; retrospective study; seroprevalence; Taiwan; vaccination; AIDS-Related Opportunistic Infections; confidence interval; Hepatitis B virus; Hepatitis B, Chronic; HIV Seropositivity; immunology; incidence; middle aged; procedures; vaccination; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Confidence Intervals; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Antibodies; HIV Seropositivity; HIV-1; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Seroepidemiologic Studies; Taiwan; Vaccination; Young Adultjournal article10.1038/ajg.2008.159192590782-s2.0-65449153663